Past events
First Quarter of 2025 Financial Results and Business Update – Press Release Only
May 20, 2025
Tübingen
Fourth Quarter and Full-Year 2024 Financial Results and Business Update – Conference Call & Webcast
April 10, 2025
CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, and provide business updates for the fourth quarter and full-year 2024 on Thursday, April 10, 2025. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.
The corresponding press release and the link to the webcast can be found below.
J.P. Morgan 43rd Annual Healthcare Conference 2025, San Francisco
January 13-15, 2025
The CureVac executive management team will be on the ground in San Francisco during the week of the JP Morgan Healthcare Conference. We welcome the opportunity to connect in person. Coordination of our meeting schedule is supported by Precision AQ, please see first link below. To request a meeting, please reach out to Amanda Isacoff, see email below.
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
Financial Results and Business Update for the Third Quarter and First Nine Months 2024 – Conference Call & Webcast
November 12, 2024
CureVac N.V. (Nasdaq: CVAC) will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.
The corresponding press release and the link to the webcast can be found below.
12th International mRNA Health Conference
November 12-14, 2024
Boston, USA
- Press Release
- Conference Website
- CureVac's tailored LNP platforms to deliver mRNA for prophylactic and therapeutic applications
- Development of a multiepitope mRNA cancer vaccine for glioblastoma - first results of Phase I human study
- An mRNA-based FimH ferritin nanoparticle vaccine against UPEC is highly immunogenic in rodents
- mRNA sequence parameters and formulation optimization increase mRNA therapeutics performance
- Enhancing TCRtg T cell therapy efficacy in solid tumors using mRNA-based vaccination
39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 8-10, 2024
Houston, USA
- Press Release
- Conference Website
- Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma
- mRNA vaccination enhances TCRtg T cell therapy efficacy in solid tumors
- Identification and validation of a T cell receptor recognizing shared HLA-A02:01 presented epitope from TP53 frameshift
Second Quarter of 2024 Financial Results and Business Update – Press Release Only
August 15, 2024
Tübingen
Goldman Sachs 45th Annual Global Healthcare Conference
June 12, 2024
Miami
Downloads
- Pressemitteilung
- Präsentation (Englischsprachig)
- Transkript (Englischsprachig)
First Quarter of 2024 Financial Results and Business Update – Press Release Only
May 23, 2024
Tübingen